ArticleClinical and translational gastroenterology2026
Sleep Architecture Screening in Hospitalized Patients With Inflammatory Bowel Diseases: A Prospective Propensity Score-Matched Analysis.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionTo evaluate the effectiveness of sleep architecture screening in hospitalized patients with inflammatory bowel diseases (IBD) from the viewpoint of long-term survival from IBDs worsening.
methodsA total of 1,024 patients were prospectively enrolled and stratified into screening cohort, receiving sleep architecture screening through the polysomnography approach, and control cohort matched by a 1:1 propensity score method. Primary endpoint was survival from disease progression including treatment escalation, severe infection, rehospitalization, emergency visit, or surgeries within 12 months after discharge. Secondary outcomes included complications and quality-adjusted life years.
resultsThe screening cohort identified that 53.5% of patients experienced sleep deprivation. N1, N2, N3, and rapid eye movement sleep accounted for 6.8%, 62.0%, 14.9%, and 16.3% of their total sleep time. During a mean follow-up of 8.6 ± 4.5 months, 26.8% and 46.6% of cases reported an IBD-related events in screening and control cohorts ( P = 0.005). The mean survival time from disease worsening was significantly longer in patients receiving screening than those in control cohort (11.68 [95% CI: 11.03-12.32] vs 9.46 [95% CI: 8.86-10.06] months, log-rank test P < 0.001), yielding a hazard ratio of 0.684 (95% CI: 0.554-0.746). Superiority was met because the 95% CI fell within the predefined superiority margin of 0.75. The means quality-adjusted life years across all time points were significantly higher in screening cohort compared with controls (all P < 0.05). No serious complications were observed. DISCUSSION: Sleep architecture screening combined with specialized interventions in patients with IBD provided a better long-term survival from disease progression, resulting in a significant improvement in patients' quality of life within a 12-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.